Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects

NCT03471130 is registered in ClinicalTrials.gov with Tanabe Pharma America, Inc. as lead sponsor.

NCT NCT03471130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects
Lead sponsor
Tanabe Pharma America, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 23, 2018
Completion date
October 19, 2018
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer